et al.. Lipoprotein-associated phospholipase A activity is increased in patients with definite familial hypercholesterolemia compared with other forms of hypercholesterolemia. Nutrition, Metabolism and Cardiovascular Diseases, Elsevier, 2018, 28 (5), pp.ABSTRACT Background: Lipoprotein-associated phospholipase A2 (Lp-PLA2) plays a key role in atherosclerosis development. It is considered a marker of increased risk of cardiovascular disease (CVD) and plaque vulnerability. Familial hypercholesterolemia (FH) is a genetic disorder characterized by elevated plasma levels of low-density lipoprotein cholesterol and a higher prevalence of early CVD. Objective: Our aim was to evaluate the differences in Lp-PLA2 activity in a population of hypercholesterolemic patients with and without definite FH. Methods: Hypercholesterolemic patients were consecutively recruited. Definite FH was defined according to Dutch Lipid Clinic Network criteria ≥ 8. All patients underwent routine clinical examination and biological assessments and Lp-PLA2 activity was measured in blood samples. Results: Among 469 patients, 118 had a definite diagnosis of FH. Lp-PLA2 activity was significantly higher in definite FH patients compared to non-definite FH patients (206.5 ± 54.5 vs. 180.8 ± 48.4 nmol/min/mL, p <0.0001). Lp-PLA2 positively correlated with total cholesterol, LDL-C and apolipoprotein B and negatively with HDL-C and apolipoprotein A-1. In multivariate analysis, definite FH diagnosis, LDL-C, HDL-C and statin treatment remained correlates of Lp-PLA2 independently of systolic blood pressure.
INTRODUCTION

Lipoprotein-associated phospholipase A2
Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a calcium-independent enzyme mainly produced by macrophages. Lp-PLA2 has been shown to play a key role in the development of atherosclerosis due to its pro-inflammatory and pro-oxidative effects 1 . Lp-PLA2 is synthesized within the atherosclerotic plaque and circulates bound to LDL-C particles 2 . By the hydrolysis of oxidized LDL-C particles, Lp-PLA2 generates bioactive lipid products (lysophosphatidylcholine and oxidized free fatty acids) which can activate and sustain the atherosclerosis process 3, 4 . Lp-PLA2 is also implicated in endothelial dysfunction 5 , plaque vulnerability 6, 7, 8 and has been associated with inflammation within the atherosclerotic plaque 9 .
Furthermore, elevated Lp-PLA2 levels were related to increased risk of coronary disease, stroke, and vascular mortality in several large scale prospective studies 10 .
However, little data exists in the specific population of patients with familial hypercholesterolemia (FH) which is an autosomal dominant lipoprotein metabolism disorder characterized by elevated plasma levels of low-density lipoprotein cholesterol (LDL-C) 11 . FH results from genetic heterozygous (heFH) or homozygous (hoFH) mutation in the low density lipoprotein receptor gene (LDLR), apolipoprotein B-100 gene (APOB) or proprotein convertase subtilisin/kexin type 9 gene (PCSK9) 11 . FH patients exhibit early atherosclerotic lesions 12, 13 with premature CVD compared to non-FH patients 14, 15 . Prevalence of CVD among heFH has been estimated to be about 33% 16 with a CVD increased risk by 8 to 17-fold vs. non-FH subjects. In patients untreated with statins, angina and acute myocardial infarctions can be observed early in life, even before 40 years old 17 .
Our aim was to evaluate Lp-PLA2 activity in a population of hypercholesterolemic patients with and without a clinical confirmed definite FH.
MATERIAL AND METHODS
Study population
Patients were consecutively recruited at our outpatient clinic (Cardiovascular Prevention Unit,
Institute of Cardiometabolism and Nutrition, La Pitié-Salpêtrière-Charles Foix University
Hospital, APHP, Paris, France) between June 2014 and June 2015. Only subjects with hypercholesterolemia were eligible for enrolment in this study. Hypercholesterolemia was defined according to patient's records as: LDL-C >4.14 mmol/L or/and treatment with statin.
FH groups and Dutch Lipid Clinic Score were determined using patient's files. Patients were included and divided into two subgroups:
-Definite FH (DFH) group defined according to the Dutch Lipid Clinic Network criteria 18, 19 with a score ≥8;
-Non-definite FH (NDFH) group of patients with Dutch Lipid Clinic Network criteria score <8.
Exclusion criteria were: LDL-C ≤1.3 mmol/L without lipid lowering treatment, high-density lipoprotein cholesterol (HDL-C) ≥2.6 mmol/L or ≤ 0.39 mmol/L; triglycerides (TG) ≥11.4 mmol/L; fasting glucose ≥10 mmol/L; history or treatment of thyroid disease; FH homozygous status. The aim for those exclusions was to define a homogenous population of patients with hypercholesterolemia.
All patients underwent routine clinical examination and biological assessments. In addition, Lp-PLA2 activity was assessed. Arterial hypertension (AH) was defined as arterial blood pressure (BP) >140/90 mmHg and/or antihypertensive treatment; type 2 diabetes (T2D) as fasting plasma glucose >6.94 mmol/L and/or glucose lowering treatment. Cigarette smoking (yes/no), body mass index (BMI) (weight in kilograms divided by the square of height in meters) and waist circumference were also evaluated. The study was carried out according to the principles outlined in the Declaration of Helsinki. Approval of the local Ethics Committee was obtained and informed consent was signed by all participants.
Laboratory methods
Lipid analysis
Fresh venous blood was collected in gel-containing Vacutainer® tubes (Becton-Dickinson, Plymouth, UK), then centrifuged at 4,500 rpm at 4°C for 10 minutes.
Fresh serum lipids were analysed by using routine methods on a Konelab 30i analyser (Thermo Electron Corporation). TG were measured by using an enzymatic method with colorimetric detection (Diasys France Condom) 20 . Total cholesterol (TC), direct LDL-C and direct HDL-C were determined using automated enzymatic methods (Konelab Thermo Fisher Scientifics, Asnières sur Seine, France) 21, 22, 23 . LDL-C was calculated by the Friedewald formula when TG <3.9 mmol/L 24 and directly dosed when TG were between 3.9 and 11.4 mmol/L. ApoA-I, apoB and Lp(a) were measured by immunonephelometry using anti-ApoA-I, anti-ApoB and anti-apo(a) antisera and a BN II nephelometer analyser from Siemens (Siemens Healthcare Diagnostics S.A.S, Saint Denis France; inter-and intra-assay coefficients of variation <4%) 25 .
Measurement of lipoprotein-associated phospholipase A2 (Lp-PLA2) activity
Measurement of Lp-PLA2 activity was performed with automated colorimetric method on Konelab 30i analyser, by using a rate reaction assay with 1-myristoyl-2-(4nitrophenylsuccinyl) phosphatidylcholine as substrate (Diadexus Inc. South San Francisco.
CA. Eurobio, France). Units were expressed as nmol platelet activating factor (PAF) hydrolysed per minute per mL of serum (nmol/min/mL) 26 . All assays were performed in the Department of Metabolic Biochemistry of Pitié-Salpêtrière -Charles Foix Hospital.
Statistical analysis
All continuous variables were described by their mean ± standard deviation (SD) and proportions (%) for categorical variables. The differences between groups were evaluated by Student's t test for continuous variables and χ 2 test for categorical variables. Correlations between Lp-PLA2 and lipid parameters were assessed using Pearson's correlation coefficient except for Lp(a) and TG where Spearman's rank correlation coefficients were provided.
Multivariate linear regression analysis was used to assess the independent contribution of the variables. A p value <0.05 was considered significant. JMP® Statistical Software, Version 11, SAS Institute Inc., Cary, NC, was used.
RESULTS
Our population consisted of 469 subjects. Among them, 118 (25.1%) were classified into the definite FH group. Among DFH subjects, 51 had a known heterozygous mutation of LDLR, APOB or PCSK9 gene. The clinical and biochemical characteristics of the whole population, as well as in DFH and in NDFH subjects are shown in Table 1 . The mean Lp-PLA2 activity of the whole population was 187.3 ± 51.2 nmol/min/mL, with a significant difference between males and females (195.9 ± 48.5 vs. 178.0 ± 52.4 nmol/min/mL respectively, p 0.0001, data not shown). No difference in Lp-PLA2 levels was found in the DFH group among subjects with known mutations and subjects without known mutations (210.1 ± 50.5 and 203.8 ± 57.5 nmol/min/mL respectively, p 0.5330, Additional Figure 1 ).
Lp-PLA2 activity was significantly higher in DFH subjects than it was in NDFH subjects (206.5 ± 54.5 vs 180.8 ± 48.4 nmol/min/mL, p <0.0001). DFH subjects were significantly younger than NDFH and less likely to suffer from diabetes or hypertension. Moreover, DFH subjects also exhibited lower HbA1c, TG, ApoA-1 levels, blood fasting glucose and blood pressure (BP) levels than NDFH. In opposite, they had higher TC, LDL-C and ApoB levels than NDFH subjects. Values of HDL-C and Lp(a) as well as the percentage of patients under statin treatment were identical in both groups. Figure   2 ). Partial correlation of Lp-PLA2 with ApoB and LDL showed that LDL-C and ApoB remains associated with Lp-PLA2 (r adj ApoB = 0.12, p <0.01; r adj LDL-C = 0.12, p <0.01). Non-HDL-C did not remain correlated with Lp-PLA2 when adjusted with LDL-C (r adj LDL-C = -0.03, p 0.86).
In a multivariate analysis, definite definite FH diagnosis as well as LDL-C, HDL-C and statin treatment remained correlated with Lp-PLA2 independently of systolic BP. Inclusion of ApoB in the model in replacement of LDL-C did not change the outcome of the analysis.
Sex was independently related with Lp-PLA2 (Table 3) . Separate multivariate analysis in DFH and NDFH patients showed minor differences in Lp-PLA2 determinants but LDL-C and HDL-C remained significantly associated to Lp-PLA2 (Additional Tables 1 and 2) . 
DISCUSSION
In this study, we found that Lp-PLA2 activity in hypercholesterolemic subjects was independently higher in subjects with a clinically confirmed definite FH than in subjects with a non-definite FH according to Dutch Lipid Clinic Network criteria.
Our results extend the results of Tsimihodimos et al. 27 who found higher Lp-PLA2 activity in FH patients (carrying hetero and homozygous mutations) compared to non-FH hypercholesterolemic subjects and controls in a smaller population. Moreover, in our study, definite FH status and LDL-C levels both independently correlated to Lp-PLA2 activity.
As observed here as well as in some previous studies 5, 27 , Lp-PLA2 activity correlates strongly and positively with LDL-C while negatively with HDL-C. The positive relationship with LDL-C may be explained by the fact that Lp-PLA2 is mainly associated with apoB-containing lipoproteins (primarily with LDL), i.e. 70-75% when expressed in mass, and 90-95% when expressed in activity 28, 29, 30 . This difference in assay procedure could also explain why we found a negative correlation with HDL-C despite about 30% of Lp-PLA2 being carried by HDL particles 31 . Several lines of evidence suggest that the Lp-PLA2 roles in atherosclerosis pathophysiology may depend on the type of lipoprotein particles with which it is associated to 32 . It seems that only LDL-associated Lp-PLA2 exerts pro-inflammatory activity while HDL-associated Lp-PLA2 seems to have an anti-atherogenic role 33 . HDL prevents or inhibits the formation of LDL-derived oxidized phospholipids 34 by the action of at least four specific enzymes present on its surface, including HDL-associated Lp-PLA2. Since oxidized phospholipids are the target of hydrolysis by Lp-PLA2, its activity can be reduced by increasing HDL concentration.
The inverse relationship between Lp-PLA2 activity and HbA1c was also observed in previous studies 35, 36 . It may be explained by the distribution of Lp-PLA2 among lipoprotein particles.
In diabetic subjects 37 in particular, Lp-PLA2 is associated mainly with HDL particles and the Lp-PLA2 glycosylation process leads to a greater activity of HDL-associated Lp-PLA2 38 .
While mendelian randomization studies may suggest otherwise 39 , there are some evidence for an active role of Lp-PLA2 in atherosclerosis 40 . As Lp-PLA2 hydrolyses oxidized phospholipids in LDL-C particles to release oxidized fatty acids at the sn-2 position and lysophosphatidylcholine 9 its activity can enhance plaque inflammation 9 . Hence, upregulation of Lp-PLA2 has been demonstrated within the plaque necrotic core and in macrophages prone to rupture plaques 41 . Inflamed vulnerable plaques have been associated with a higher prevalence of coronary heart disease 42, 43 in the general population and increased circulating
Lp-PLA2 levels have been associated with higher plaque vulnerability 8 . Concerning FH, Caballero et al. 44 found an increased prevalence of lipid-rich atherosclerotic plaques in FH using magnetic resonance imaging. Moreover, Van Den Oord et al. 45 found that FH subjects more frequently exhibited atherosclerotic plaques neovascularization, a sign of plaque vulnerability. Along with the early and lifelong exposure to elevated LDL-C levels, those observations of more vulnerable plaques in FH patients could partially explain why FH patients develop premature symptomatic atherosclerosis. Our study suggests that the increased CVD risk in patients with FH could be partly explained by the arterial wall inflammation associated with plaque vulnerability and witnessed by high circulating Lp-PLA2 levels. This hypothesis may be hampered by the STABILITY trial 46 failure to prove that pharmacological Lp-PLA2 activity lowering could decrease cardiovascular events in a high risk population of patients. However, no specific data on FH patients within the STABILITY trial were published. Also, in another trial 51 , while the darapladib molecule inhibited necrotic core growth of human coronary plaques, it failed to prevent cardiovascular events in a phase III trial.
In our study, statin treatment was negatively correlated to Lp-PLA2 levels independently of LDL-C and definite FH status. This is coherent with the well-known effect of statins which decrease Lp-PLA2 in general populations 47 but also in selected FH population 48, 49 Our study extend those results in a larger population of real life definite FH patients. Beyond their LDL-C lowering effect, statins exhibit pleiotropic effects. One of them is to stabilize atherosclerotic plaques by reducing foam cell formation and inflammatory process and by inhibiting the macrophages matrix metalloproteinases production 50 . High Lp-PLA2 levels observed in our population may also be explained by the fact that only three quarters of definite FH subjects were under statin treatment. Our results further reinforce the concept that cardiovascular protection with statins may be partially explained by anti-inflammatory effects, perhaps on Lp-PLA2 especially.
Our study exhibits some limitations. First, it is a cross sectional study and therefore we cannot determine causality. Then, we did not analyse the different lipoproteins particles in our study.
Also, we did not measure Lp-PLA2 mass, but Lp-PLA2 activity has several technical advantages 30 including in the pre-analytic phase that makes it more easy to use in clinical practice. Another limit is that without the certainty of genetic diagnosis, it can be assumed that a variable percentage of FH patients were attributed to the NDFH group. This however did not prevent us from finding statistical differences between the groups.
CONCLUSION
In a population of hypercholesterolemic patients, we found that Lp-PLA2 activity was higher in patients with a clinically confirmed definite FH independently of LDL-C levels and statin treatment in comparison with subjects with a non-definite FH according to Dutch Lipid Clinic Network criteria. These results highlight the particular phenotype of FH within the vast population of patients with hypercholesterolemia. In addition to early and lifelong elevated LDL-C, the high levels of arterial inflammation may also be involved in the premature onset of CVD in FH patients. Their high cardiovascular risk can be prevented by adequate therapeutic strategies using statin anti-inflammatory pleiotropic effects. Our results also reinforce the need for proper identification of this disease which affects 1/200 people in Western countries. 
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